1. Please check and comment entries here.
Table of Contents

    Topic review

    Management of Low-Risk Thyroid Cancers

    Subjects: Oncology | Surgery
    View times: 6
    Submitted by: Renato Patrone


    Thyroid cancer is the most common endocrine malignancy, representing 2.9% of all new cancers in the United States (US). It has an excellent prognosis, with a five-year relative survival rate of 98.3%, and has a higher frequency in females than males, with ratio of 3:1. Differentiated thyroid cancer (DTC) represents 90% of all thyroid malignancies and includes three main types: papillary thyroid cancer (PTC), the most common type, comprising 85% of all DTC; follicular thyroid cancer (FTC); and the rare subtype, Hürthle (oncocytic) cell thyroid cancer (2–5%).

    1. Introduction

    Thyroid cancer is the most common endocrine malignancy, representing 2.9% of all new cancers in the United States (US). It has an excellent prognosis, with a five-year relative survival rate of 98.3%, and has a higher frequency in females than males, with ratio of 3:1 [1]. Differentiated thyroid cancer (DTC) represents 90% of all thyroid malignancies and includes three main types: papillary thyroid cancer (PTC), the most common type, comprising 85% of all DTC; follicular thyroid cancer (FTC); and the rare subtype, Hürthle (oncocytic) cell thyroid cancer (2–5%) [2].

    In the last ten years, the incidence of DTC has dramatically increased. This tendency is mainly as a result of the diffusion of imaging systems, the use of ultrasound-guided Fine Needle Aspirations Cytology (FNAC), and improvements in histological evaluations [3][4].

    Actually, papillary microcarcinomas (PMCs) represents the most diagnosed thyroid tumors, with a 35% incidence of occult papillary thyroid microcarcinomas in autopsy studies [5]. The increased diagnosis of these malignancies, associated with a low risk of recurrence and death, has led to the need for redefining of the multimodal therapeutic approach to avoid potential overtreatments. With regard to treatment, historically, the only option was surgery. In the last few years, active surveillance (AS) has been established as an alternative approach; it is aimed at identifying patients who would likely benefit from rescue surgery [6].

    Considering the data in the literature and the available evidence, we reviewed the current management of low-risk DTC, and PMCs in particular, to better clarify the indications for active surveillance for low-risk thyroid cancers.

    2. Materials and Methods

    According to the PRISMA flowchart (Preferred Reporting Items for Systematic reviews and Meta-Analyses), a systematic search was performed of electronic databases (PubMed, Web of Science, Scopus, and EMBASE). We used medical subject headings (MeSH) and free-text words, using the following search terms in all possible combinations: “differentiated thyroid cancer”, “micro papillary cancer”, “management”, and “active surveillance”. The last search was performed in May 2021. Attention was focused on the following primary outcomes: growth of the primary tumor, metastatic disease (lymph node or extra nodal), tumor recurrence after delayed thyroid surgery (DTS), and thyroid-cancer-related mortality. The secondary outcomes selected were decreased volume of primary tumor (>3 mm), overall mortality, and incidence of/indication for thyroidectomy.

    The retrospective application of the surveillance criteria to patients surgically treated for thyroid nodules was not one of inclusion criteria for the studies reporting on AS of low-risk PTC; AS was limited to employment of surveillance strategies. Low-risk PTC was defined as T1a or T1b, N0, M0 disease. The search strategy was limited to articles written in the English language; moreover, papers on animal studies, review articles, editorials, and case series were excluded.

    R.P. and G.C., two independent authors, analyzed all the papers, selected the suitable manuscripts, and performed the data extraction independently. All duplicate studies were removed. Two other authors (N.V. and S.M.) then checked the eligibility of the studies selected. Discrepancies were resolved by consensus.

    3. Development and Findings

    We identified a total of 2976 articles, of which 87 articles were selected for full text review. After full text review, 14 studies were included for the final analysis. The results are summarized in the PRISMA flowchart ( Figure 1 ) [7][8][9][10][11][12][13][14][15][16][17][18][19][20].

    Figure 1. PRISMA flowchart.

    A total number of 4830 patients under AS were included in this review.

    All studies assessed tumor growth during AS; a total of 451/4830 (9.4%) patients experienced an increase in diameter of up to 3 mm. Conversely, in five studies, a decrease in tumor size > 3 mm was assessed in 172/1324 (12.9%) patients during AS.

    DTS after AS was performed in 609/4830 (12.6%) patients, as reported by all authors. Ten authors reported involvement of cervical lymph nodes during AS in 88/4213 (2.1%) patients, while in six studies, 4/3589 (0.1%) patients were reported to have extra-nodal metastatic disease. No study reported mortality due to thyroid cancer during AS.

    4. Conclusions

    Active surveillance should be proposed for low-risk PMC only after clinical trials proving the validity of this approach. For high-risk PMC, (lymph node or distant metastasis, extra thyroid extension, closeness to recurrent laryngeal nerve or trachea, high-grade cytology, or growth during observation), a surgical approach (lobectomy with or without paratracheal dissection) is necessary. Better knowledge of papillary cancer natural history and biological behavior might be useful in the design of multimodal management.

    This entry is adapted from 10.3390/jcm10163569


    1. Bethesda, M.D.; SEER Cancer Stat Facts. Thyroid Cancer. National Cancer Institute. Available online: https://seer.cancer.gov/statfacts/html/thyro.html (accessed on 10 May 2021).
    2. Stewart, L.A.; Kuo, J.H. Advancements in the treatment of differentiated thyroid cancer. Ther. Adv. Endocrinol. Metab. 2021, 12, 20420188211000251.
    3. Davies, L.; Welche, H.G. Current thyroid cancer trends in the United States. JAMA Otolaryngol. Head Neck Surg. 2014, 140, 317–322.
    4. Davies, L.; Morris, L.G.; Haymart, M.; Chen, A.Y.; Goldenberg, D.; Morris, J.; Ogilvie, J.B.; Terris, D.J.; Netterville, J.; Wong, R.J.; et al. AACE Endocrine Surgery Scientific Committee. The increasing incidence of thyroid cancer. American association of clinical endocrinologists and American college of endocrinology disease state clinical review. Endocr. Pract. 2015, 21, 686–696.
    5. Harach, H.R.; Franssila, K.O.; Wasenius, V.M. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 1985, 56, 531–538.
    6. Ito, Y.; Uruno, T.; Nakano, K.; Takamura, Y.; Miya, A.; Kobayashi, K.; Yokozawa, T.; Matsuzuka, F.; Kuma, S.; Kuma, K.; et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003, 13, 381–387.
    7. Kim, H.I.; Jang, H.W.; Ahn, H.S.; Ahn, S.; Park, S.Y.; Oh, Y.L.; Hahn, S.Y.; Shin, J.H.; Kim, J.H.; Kim, J.S.; et al. High serum TSH level is associated with progression of papillary thyroid microcarcinoma during active surveillance. J. Clin. Endocrinol. Metab. 2018, 103, 446–451.
    8. Fukuoka, O.; Sugitani, I.; Ebina, A.; Toda, K.; Kawabata, K.; Yamada, K. Natural history of asymptomatic papillary thyroid microcarcinoma: Time-dependent changes in calcification and vascularity during active surveillance. World J. Surg. 2016, 40, 529–537.
    9. Ito, Y.; Miyauchi, A.; Kihara, M.; Higashiyama, T.; Kobayashi, K.; Miya, A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014, 24, 27–34.
    10. Tuttle, R.M.; Fagin, J.A.; Minkowitz, G.; Wong, R.J.; Roman, B.; Patel, S.; Untch, B.; Ganly, I.; Shaha, A.R.; Shah, J.P.; et al. Natural history and tumor volume kinetics of papillary thyroid cancers during active surveillance. JAMA Otolaryngol. Head Neck Surg. 2017, 143, 1015–1020.
    11. Oh, H.-S.; Ha, J.; Kim, H.I.; Kim, T.H.; Kim, W.B.; Lim, D.-J.; Kim, S.W.; Shong, Y.K.; Chung, J.H.; Baek, J.H. Active surveillance of low-risk papillary thyroid microcarcinoma: A multi-center cohort study in Korea. Thyroid 2018, 28, 1587–1594.
    12. Kwon, H.; Oh, H.-S.; Kim, M.; Park, S.; Jeon, M.J.; Kim, W.B.; Shong, Y.K.; Song, D.E.; Baek, J.H.; Chung, K.-W.; et al. Active surveillance for patients with papillary thyroid microcarcinoma: A single center’s experience in Korea. J. Clin. Endocrinol. Metab. 2017, 102, 1917–1925.
    13. Sugitani, I.; Toda, K.; Yamada, K.; Yamamoto, N.; Ikenaga, M.; Fujimoto, Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: Our treatment strategies and outcomes. World J. Surg. 2010, 34, 1222–1231.
    14. Sanabria, A. Active surveillance in thyroid microcarcinoma in a Latin-American cohort. JAMA Otolaryngol. Head Neck Surg. 2018, 144, 947–948.
    15. Oda, H.; Miyauchi, A.; Ito, Y.; Yoshioka, K.; Nakayama, A.; Sasai, H.; Masuoka, H.; Yabuta, T.; Fukushima, M.; Higashiyama, T.; et al. Incidences of Unfavorable Events in the Management of Low-Risk Papillary Microcarcinoma of the Thyroid by Active Surveillance Versus Immediate Surgery. Thyroid 2016, 26, 150–155.
    16. Gorshtein, A.; Slutzky-Shraga, I.; Robenshtok, E.; Benbassat, C.; Hirsch, D. Adherence to Active Surveillance and Clinical Outcomes in Patients with Indeterminate Thyroid Nodules Not Referred for Thyroidectomy. Eur. Thyroid J. 2021, 10, 168–173.
    17. Rozenbaum, A.; Buffet, C.; Bigorgne, C.; Royer, B.; Rouxel, A.; Bienvenu, M.; Chereau, N.; Menegaux, F.; Leenhardt, L.; Russ, G. Outcomes of active surveillance of EU-TIRADS 5 thyroid nodules. Eur. J. Endocrinol. 2021, 184, 677–686.
    18. Hu, Y.L.; Cao, X.Y.; Zhou, Y.R.; Ye, X.H.; Wang, J.X.; Li, X.; Rong, R.; Shen, M.P.; Wu, X.H. Management of Sonographically Suspicious Thyroid Nodules 1 cm or Smaller and Candidacy for Active Surveillance: Experience of a Tertiary Center in China. Endocr. Pract. 2021, 17, S1530–S1891.
    19. Rosario, P.W.; Mourão, G.F.; Calsolari, M.R. Active Surveillance in Adults with Low-Risk Papillary Thyroid microcarcinomas: A Prospective Study. Horm. Metab. Res. 2019, 51, 703–708.
    20. Oh, H.S.; Kwon, H.; Song, E.; Jeon, M.J.; Kim, T.Y.; Lee, J.H.; Kim, W.B.; Shong, Y.K.; Chung, K.W.; Baek, J.H.; et al. Tumor Volume Doubling Time in Active Surveillance of Papillary Thyroid Carcinoma. Thyroid 2019, 29, 642–649.